Douglas M. Baker, Jr.
Analyst · Canaccord Genuity
Yes, from an M&A front I would say, with the promising property has been increasing and that's not only in healthcare, but that's across the board, as we started I would say re-emphasizing bolt-on acquisitions, be it geographic expansion, newer share play or new technology. And certainly our healthcare lift has benefited too from getting back on the focus which is I think, it’s a natural stage of where we are. Come to healthcare, but we don’t like the results that we are seeing, we understand many of the drivers. The business is working hard at how improve their ability to go drive new business impact. So fundamentally in the U.S. in many of the areas that we compete, we’ve had same store sales equivalent challenges. This isn’t unique to us. It’s pretty much across the board in many parts of the healthcare industry. We’ve seen this in many environments before and we overcome it by selling through it, and right now our sales efforts aren’t significant enough to overcome negative same-store sales. I mean it is about as simple as that. So our business is sticky, we are keeping it. There is a lot of the metrics that we like, but we are really if you will, in the shop working on, how do we drive that forward and work on it. Now I will say that's a competency that we have in this company, we are good at this and we are quite confident, we’ll get this move in the right direction and the healthcare teams are all over it, but it’s not going to be an overnight success. So we are not going to start seeing the sixth to eighth, high single-digit collectively for a number of quarters and so we’ve got a so ramping-up sales, which we believe we’ll start seeing, but we are not going to be where, we are comfortable for the several quarters.
John S. Quealy – Canaccord Genuity, Inc.: Okay, and then a quick follow-up on Global Energy in terms of the guidance in the back-half of the year, was some acceleration in growth. I would assume that’s still more geared towards upstream and offshore than downstream relatively incremental benefits in the back-half of the year?